New York, November 14, 2016 -- Moody's Investors Service (Moody's) today assigned a B3 instrument rating to Envision Healthcare Corporation's ("Envision") new $750 million senior unsecured notes. Proceeds from the new senior unsecured notes will be used alongside a $3.3 billion senior secured term loan and a resized $850 million ABL revolver to refinance legacy debt at Envision and AmSurg Corp. ("AmSurg") in conjunction with the two companies' planned merger. The new notes will be pari-passu with other existing senior unsecured indebtedness of the combined firm.

Vollständigen Artikel bei Moodys lesen